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CYP27A1 (sterol 27-hydroxylase) catalyses an important sterol
elimination pathway in the human macrophage, and consequently
may protect against atherosclerosis. We studied the expression and
regulation of CYP27A1 in a human macrophage-like cell-line,
THP-1, and primary HMDMs (human monocyte-derived macro-
phages). In both macrophage cell types, we found that CYP27A1
expression is independent of cellular cholesterol levels and of
LXR (liver X receptor)-dependent control of transcription. How-
ever, the RXR (retinoid X receptor) ligand, 9-cis-retinoic acid, up-
regulates CYP27A1 expression. Of the RXR heterodimeric part-
ners tested, PPAR (peroxisome-proliferator-activated receptor)
γ ligands significantly increased CYP27A1 mRNA levels. Its
reversal by a PPARγ antagonist demonstrated the specificity of
this effect. Interestingly, HMDMs express markedly higher levels
of CYP27A1 than THP-1 macrophages, and this difference was
reflected in both protein levels and enzyme activities between
the two cell types. In conclusion, stimulation of CYP27A1 by
PPARγ may represent a key previously unrecognized mechanism
by which PPARγ protects against atherosclerosis.
Key words: atherosclerosis, cholesterol, liver X receptor
(LXR), macrophage, peroxisome-proliferator-activated receptor γ
(PPARγ ), sterol 27-hydroxylase (CYP27A1).
INTRODUCTION
Accumulation of excess cholesterol within intimal macrophages
to generate lipid-laden foam cells is a key early event in the devel-
opment of atherosclerosis. Processes that contribute to the elim-
ination of cholesterol from macrophages are therefore potentially
protective against atherosclerosis. These mechanisms involve
both export of cholesterol to extracellular acceptors, such as apoA-
1 (apolipoprotein A-1), and catabolism of cholesterol to more
polar sterols that can be exported more readily than cholesterol,
largely independent of such acceptors.
Efflux of cholesterol from macrophages to apoA-1 is dependent
on a membrane transporter, ABCA1 (ATP-binding cassette trans-
porter protein A1) [1]. In addition, macrophages produce and
secrete apoE (apolipoprotein E), an endogenously generated
cholesterol acceptor that may contribute to cholesterol removal
[2]. Expression of both ABCA1 and apoE is regulated by cell
sterol content, mediated through the nuclear receptors, LXR (liver
X receptor) α and PPAR (peroxisome-proliferator-activated re-
ceptor) γ [3]. An alternative export route, involving catabolism of
cholesterol to more polar sterols, is catalysed by CYP27A1 (sterol
27-hydroxylase). This mitochondrial cytochrome P450 enzyme
was first discovered in the liver, where it catalyses multiple oxi-
dation reactions in bile acid synthesis [4]. Subsequent studies have
revealed expression of CYP27A1 in a wide range of extrahepatic
tissues and cells, including endothelial cells and macrophages
[5–7]. The human macrophage exhibits a particularly high ex-
pression of CYP27A1 and capacity to convert cholesterol into
27-hydroxycholesterol, 3β-hydroxy-5-cholestenoic acid [8] and
downstream water-soluble products [9].
Several lines of evidence suggest that CYP27A1 may be an
important defence mechanism against cholesterol accumulation
in the macrophage. First, a functional deficiency in this enzyme in
humans leading to a rare disorder, CTX (cerebrotendinous xan-
thomatosis), is associated with sterol deposition in tissue macro-
phages and an increased risk of developing premature athero-
sclerosis, despite normal circulating cholesterol levels [8].
Secondly, it is estimated that there is a significant daily flux
of CYP27A1-derived sterol products from extrahepatic sources
to the liver, where they can be catabolized further and eventually
excreted as bile acids [10], indicating that this enzyme contributes
to removal of peripheral tissue cholesterol. In addition, CYP27A1
is substantially up-regulated in atherosclerotic lesions, co-local-
izing mainly with macrophages in advanced lesions [7,11].
Studies on the regulation of CYP27A1 have largely examined
hepatic expression of this enzyme. In the liver, expression is
increased by glucocorticoids [12], growth hormone and insulin-
like growth hormone-1 [12,13], and is decreased by cyclosporin,
bile acids and fibrates [13], consistent with its role as an alternative
route for hepatic bile acid synthesis. Much less is known about
the control of CYP27A1 levels in macrophages. Its expression
increases during monocyte-to-macrophage differentiation [14]
and is suppressed by some inflammatory mediators (interferon-γ
or immune complexes) [15]. While ABCA1 and apoE are up-regu-
lated by cholesterol loading in macrophages [16], little is known
of the effects of lipid status on CYP27A1 expression and activity.
Abbreviations used: ABCA1, ATP-binding cassette protein A1; ABCG1, ATP-binding cassette protein G1; AcLDL, acetylated low-density lipoprotein;
apoA-1, apolipoprotein A-1; apoE, apolipoprotein E; BCA, bicinchoninic acid; CTX, cerebrotendinous xanthomatosis; CYP27A1, sterol 27-hydroxylase;
DMEM, Dulbecco’s modified Eagle’s medium; FCS, foetal calf serum; FXR, farnesoid X receptor; LXR, liver X receptor; HMDM, human monocyte-
derived macrophage; LDL, low-density lipoprotein; LPDS, lipoprotein-deficient human serum; PBGD, porphobilinogen deaminase; PPAR, peroxisome-
proliferator-activated receptor; PPRE, PPAR-response element; PXR, pregnane X receptor; QRT-PCR, quantitative reverse transcription PCR; RT-PCR,
reverse transcription PCR; RXR, retinoid X receptor; SREBP, sterol-regulatory-element-binding protein.
1 To whom correspondence should be addressed at the Centre for Vascular Research, School of Medical Sciences, University of New South Wales,
Sydney, NSW 2052, Australia (email w.jessup@unsw.edu.au).
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In addition, CYP27A1 products, 27-hydroxycholesterol and
3β-hydroxy-5-cholestenoic acid, have been implicated as weak
endogenous ligands for LXRα in some studies [17–19], although
this is not always the case [20,21]. Thus CYP27A1 expression
might promote cholesterol elimination both directly (by meta-
bolism of cholesterol) and indirectly (by formation of products
that stimulate ABCA1 and apoE expression). In addition, overex-
pression of CYP27A1 is associated with increased efflux of
cholesterol to apoA-1, independent of ABCA1 expression [21], by
as yet undefined mechanisms. In the present study, we examined
whether control of CYP27A1 expression and activity in human
macrophages was affected by sterol loading and/or ligands for
lipid-dependent nuclear receptors.
EXPERIMENTAL
Reagents
All solvents were of HPLC grade. The following chemicals and
reagents were used, with the suppliers indicated: BSA fraction V
(Sigma), [1α,2β(n)-3H]cholesterol (specific radioactivity, 49 Ci/
mmol; Amersham Biosciences), [1,2,6-3H]7-oxocholesterol (5-
cholesten-3β-ol-7-one) (specific radioactivity, 50 Ci/mmol;
American Radiolabeled Chemicals), RPMI 1640 (Trace Bio-
sciences), DMEM (Dulbecco’s modified Eagle’s medium) (Trace
Biosciences), FCS (foetal calf serum) (Gibco BRL), PMA
(Sigma), Tri Reagent (Sigma), 22(R)-hydroxycholesterol (Sigma),
9-cis-retinoic acid (Sigma), oligo(dT) (Invitrogen); deoxy-
nucleotides (Sigma), M-MLV Reverse Transcriptase (Invitrogen),
RNasin (Promega), Red Hot DNA Polymerase (ABGene), iQ
SyBr Green Supermix (Bio-Rad), and ECL® (enhanced chemi-
luminescence) assay kit (Amersham Biosciences). Oligo-
nucleotides were synthesized by Sigma-Genosys. GW273297x,
GW3965, GW1929, GW6777 (pioglitazone), GW9662,
GW0742, GW9578, GW7647 and rosiglitazone were gifts from
GlaxoSmithKline. TO-901317 was from Cayman Chemicals.
AcLDL (acetylated low-density lipoprotein) and LPDS (lipopro-
tein-deficient human serum) were prepared from normolipidaemic
human peripheral blood as described previously [22]. White cell
concentrates and human serum were kindly supplied by the Red
Cross Blood Bank (Sydney, NSW, Australia).
Cell culture
Cells were cultured (37 ◦C, 5% CO2) in medium supplemented
with L-glutamine (2 mM) and penicillin (100 units)/streptomycin
(100 µg/ml). THP-1 cells, obtained from the A.T.C.C. (Manassas,
VA, U.S.A.), were plated (1.2 × 106 cells/ml) and grown in 10%
(v/v) FCS in RPMI 1640 (Trace Biosciences) in the presence
of PMA (50 ng/ml, 72 h) to promote differentiation into macro-
phages. HepG2 cells, also obtained from the A.T.C.C., were
plated (1.2 × 106 cells/ml) and grown in 10% (v/v) FCS in
DMEM (Trace Biosciences). HMDMs (human monocyte-derived
macrophages) were prepared from white cell buffy coat concen-
trates from healthy donors as described [23]. Purified monocytes
(>95% purity by non-specific esterase staining) were differen-
tiated into macrophages by plating (2 × 106 cells/ml) in RPMI
1640 with 10% (v/v) heat-inactivated whole human serum for
9 days.
For cholesterol loading, differentiated THP-1 cells and
HMDMs were incubated with RPMI 1640 containing LPDS
(10%, v/v) and AcLDL at final concentrations of 150 µg/ml
(THP-1) or 50 µg/ml (HMDMs) for 4 days. These conditions give
approximately the same degree of loading between the two cell
types [24,25].
For other treatments, differentiated THP-1 cells and HMDMs
were incubated for 24 h with RPMI 1640 containing 1 % (v/v)
FCS (THP-1) or 10% (v/v) LPDS (HMDMs) and 10 µM (final
concentration) of nuclear receptor ligands, except for rosiglita-
zone and pioglitazone, when 50–100 µM was used. Cells were
washed twice in PBS at room temperature (22 ◦C) before harvest-
ing with Tri Reagent for total RNA or in homogenization buffer
for mitochondrial lysates (see below). For activity assays, medium
was retained.
CYP27A1 activity
CYP27A1 activity assays were performed by measuring CYP-
27A1-dependent product formation in whole cells, as described
previously [9], using 3H-labelled sterol substrates. The initial pro-
ducts of CYP27A1 activity are 27-hydroxycholesterol and 3β-
hydroxy-5-cholestenoic acid [8], but, as we have shown pre-
viously, macrophages metabolize the majority of these to more
polar products [9]. While not fully characterized, their generation
is entirely dependent on initial CYP27A1 action, shown by com-
parison between macrophages from normal and CTX subjects
or by measurement in normal cells in the presence and absence
of the specific CYP27A1 inhibitor, GW273297x [9]. We also
showed previously that CYP27A1 acts more readily on 7-oxo-
cholesterol than on cholesterol in HMDMs. For routine assay,
activity was assessed by determination of total aqueous soluble
products +−GW273297x. Cells were incubated for 24 h with
RPMI 1640 containing BSA (1 mg/ml) plus [3H]cholesterol or
[3H]7-oxocholesterol, both at 1 µCi/culture, delivered in ethanol
(final concentration 0.1 %, w/v). Control cultures included
GW273297x (1 µM). Media were removed and centrifuged at
5000 g for 5 min to remove any detached cells. Media were
extracted with chloroform/methanol (2:1, v/v), and the aqueous-
soluble counts were measured in a Packard Tri-Carb 2100 TR
Liquid Scintillation Analyzer. Cell monolayers were washed
twice in PBS and lysed in 0.2 M NaOH (15 min, 4 ◦C) for deter-
mination of total cell protein. In some cases, 27-hydroxy-
cholesterol (lipid phase) was determined by TLC.
CYP27A1 protein expression
Mitochondrial fractions were prepared to measure CYP27A1
expression [26]. Briefly, 1 × 107 cells were washed, then scraped
into PBS on ice and centrifuged at 800 g for 5 min. The pellet was
resuspended in homogenization buffer (200 mM sucrose, 100 mM
potassium phosphate buffer, pH 7.4, 1 mM EDTA and 1 mM di-
thiothreitol), sonicated on ice (MSE sonicator) and centrifuged
(500 g, 5 min, 4 ◦C). The pellet was resuspended and centri-
fuged again under the same conditions, then lysed in 0.1% (v/v)
Triton X-100. Some aliquots were retained for determination of
protein concentration by the BCA (bicinchoninic acid) assay
(Pierce), and others were stored in SDS/PAGE loading buffer
[100 mM Tris/HCl, pH 6.8, 200 mM dithiothreitol, 4 % (w/v)
SDS, 0.2% (w/v) Bromophenol Blue and 20% (v/v) glycerol]
at −20 ◦C for subsequent electrophoresis. Samples (20 µg per
lane) were run on a SDS/10% PAGE gel. Protein was transferred
on to nitrocellulose (Hybond C), which was blocked for 1 h in
blocking solution [5% (w/v) non-fat dried milk and 0.1% (v/v)
Tween 20 in PBS]. The primary antibody was an affinity-purified
rabbit polyclonal antipeptide antibody raised against residues
15–28 of the human CYP27A1 protein (a gift from Dr David
Russell, University of Texas Southwestern Medical Centre,
Dallas, TX, U.S.A.) [27]. This was used at a dilution of 1:300
in blocking solution, incubated overnight at 4 ◦C. After washing,
the blots were incubated with a 1:5000 dilution of donkey
c© 2005 Biochemical Society
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Table 1 Primer sequences for gene expression analysis
Gene Accession number Direction Primer sequence Predicted size (bp) Reference
CYP27A1 NM 000784 Forward 5′-TGC GCC AGG CTC TGA ACC AG-3′ 311 [6]
Reverse 5′-TCC ACT TGG GGA GGA AGG TG-3′
ABCA1 NM 005502 Forward 5′-GCA CTG AGG AAG ATG CTG AAA-3′ 205 [28]
Reverse 5′-AGT TCC TGG AAG GTC TTG TTC AC-3′
GAPDH NM 002046 Forward 5′-TGA AGG TCG GAG TCA ACG GAT TTG GT-3′ 981 Present study
Reverse 5′-CAT GTG GGC CAT GAG GTC CAC CAC-3′
PBGD X04217 Forward 5′-GAG TGA TTC GCG TGG GTA CC-3′ 201 [28]
Reverse 5′-GGC TCC GAT GGT GAA GCC-3′
anti-rabbit IgG conjugated to horseradish peroxidase (Jackson
Laboratories) for 1–2 h. Bound antibodies were visualized by
ECL® and exposed to film at room temperature.
RNA extraction and RT-PCR (reverse-transcription PCR)
Cells were harvested for total RNA using Tri Reagent, according
to the manufacturer’s instructions. Concentrations of total RNA
were measured by UV spectrophotometry at 260 nm (‘DNA
Calculator’; Amersham Biosciences). For each reverse-transcrip-
tion reaction, 5 µg of total RNA was reverse-transcribed using
oligo(dT) primers (Gibco) and M-MLV (Moloney murine leu-
kaemia virus) reverse transcriptase (Gibco).
Semi-quantitative RT-PCR was performed using CYP27A1-
specific primers [6] (Table 1). These span a 311 bp sequence of
the CYP27A1 cDNA, crossing an intron of approx. 100 bp al-
lowing for distinction between amplification from contaminating
genomic DNA and that of the reverse-transcribed mRNA.
Other primers used were for ABCA1 and the housekeeping
genes GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and
PBGD (porphobilinogen deaminase) [28] (Table 1). PCR products
were verified by sequencing.
Relative ‘real time’ QRT-PCR (quantitative RT-PCR) was per-
formed using an ABI 7700 Sequence Detector (PE Biosystems)
and analysed using ABI Prism Sequence Detector Software ver-
sion 1.6.3 (PE Biosystems). iQ SyBr Green Supermix (Bio-Rad)
was used as the amplification system. The same primer sets were
used for CYP27A1, and the housekeeping gene used was PBGD.
Melting curve analysis was performed to confirm production of a
single product in these reactions.
Protein determination
The protein contents of cell lysates, mitochondrial lysates and
LDL (low-density lipoprotein) preparations were measured using
the BCA assay using BSA as a standard.
Statistical analysis
Statistical analyses used one-way ANOVA followed by Tukey’s
post-hoc test, unless otherwise stated.
RESULTS
Effect of cholesterol loading and LXR ligands on THP-1 human
macrophage expression of CYP27A1
The expression of several proteins implicated in cholesterol ex-
port from macrophages is up-regulated by cholesterol loading. As
CYP27A1 contributes to sterol elimination from human macro-
phages [29] and macrophages in cholesterol-rich human athero-
sclerotic lesions strongly express CYP27A1, we examined the ef-
fect of macrophage cholesterol loading on CYP27A1 expression.
Figure 1 RXR, but not LXR, ligands stimulate CYP27A1 expression in THP-1
human macrophages
Ligands for LXR or RXR were incubated with PMA-differentiated THP-1 cells for 24 h.
Final concentrations were 10 µM, except for TO-901317 which was 1 µM. LXR ligands:
22(R)HC, 22(R)-hydroxycholesterol; 27HC, 27-hydroxycholesterol; TO-901317; GW3965. RXR
ligand: 9-cRA, 9-cis-retinoic acid. CYP27A1, ABCA1 and GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) mRNA levels were measured using RT-PCR as described in the Experimental
section. Pooled data derived from densitometric scans of three separate experiments are
presented relative to vehicle-treated controls (means + S.E.M.). *Significantly different (P <
0.05) compared with ABCA1 control. **Only 9-cis-retinoic acid produced a significant increase
in CYP27A1 expression compared with control (ANOVA followed by Tukey’s post-hoc test).
We have shown previously that incubation with AcLDL under the
conditions used in the present study increases total cell cholesterol
3-fold, of which approx. 50% is deposited as cytoplasmic lipid
droplets [24,30], and is associated with approx. 2-fold increases
in ABCA1 mRNA and apoE protein expression [25,31,32]. In
contrast, we found that cholesterol loading had no effect on
CYP27A1 mRNA levels in THP-1 macrophages. Results from
RT-PCR, performed on RNA extracts from replicate cultures
of AcLDL-loaded THP-1 cells, showed that CYP27A1 mRNA
expression was 1.2-fold relative to non-loaded control cells
[+−0.12 (S.E.M.); P > 0.05; n = 10].
Cholesterol regulation of ABCA1 and apoE expression in
macrophages is thought to be by endogenous formation of activ-
ating ligands for the transcriptional regulator, LXRα. Consistent
with the responses to cholesterol loading, human macrophage
ABCA1 expression is stimulated by direct addition of LXR
agonists 22(R)-hydroxycholesterol, GW3965 and T0901317 [33],
while, under the same conditions, CYP27A1 expression was un-
affected (Figure 1). Interestingly, 27-hydroxycholesterol, which
acts as a weak LXR ligand in some circumstances [19], did not
significantly increase expression of ABCA1 or CYP27A1 in these
experiments. Overall, THP-1 macrophage CYP27A1 expression
c© 2005 Biochemical Society
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Figure 2 Control of CYP27A1 expression by ligands for RXR heterodimer
partners in THP-1 human macrophages
(A) Ligands for nuclear receptors, chenodeoxycholic acid (FXR), rifampicin (PXR), GW7647
and GW9578 (PPARα), GW0742 (PPARδ) and GW1929 (PPARγ ), were incubated (10 µM)
with PMA-differentiated THP-1 macrophages for 24 h. CYP27A1 mRNA levels were measured
using QRT-PCR, normalized to PBGD mRNA levels. Data are presented relative to vehicle-treated
controls and are means + S.E.M. (n = at least 3). *Significantly different (P < 0.01) compared
with control. (B) Ligands for PPARγ (GW1929 and GW6777/pioglitazone) and a PPARγ
antagonist (GW9662) were incubated (10 µM, and 50 µM for GW6777) with PMA-differentiated
THP-1 macrophages for 24 h. CYP27A1 mRNA levels were measured as in (A). Data are
means + S.E.M. (n = at least 3). Significant differences (P < 0.01) are indicated.
was unresponsive to cholesterol loading or to synthetic LXR
ligands.
RXR (retinoid X receptor) and PPARγ ligands stimulate CYP27A1
expression in THP-1 human macrophages
In contrast with the unresponsiveness of CYP27A1 expression to
cholesterol loading and LXR ligands, 9-cis-retinoic acid, a ligand
for RXRα, consistently increased CYP27A1 mRNA levels in
PMA-differentiated THP-1 cells (Figure 1). RXR is the hetero-
dimeric partner for LXR and several other lipid-activated nuclear
receptors. Some of these partners are implicated in the regulation
of other cytochrome P450 enzymes [FXR (farnesoid X receptor),
PXR (pregnane X receptor)] and/or lipid homoeostasis (PPARα,
γ , δ). Their involvement in CYP27A1 gene expression was in-
vestigated following treatment of PMA-differentiated THP-1 cells
with a range of specific agonists. Agonists for FXR (cheno-
deoxycholic acid), PXR (rifampicin), PPARα (GW9578 [34];
GW7647 [35]) and PPARδ (GW0742 [36]) had little or no effect
(Figure 2A). While these cells do not express detectable FXR,
both PPARα and PPARδ levels increase during differentiation [37]
and are functional in transcriptional control. To our knowledge,
macrophage PXR levels have not been measured. In any case,
Figure 3 Effects of RXR and PPARγ ligands on CYP27A1 activity in THP-1
human macrophages
PMA-differentiated THP-1 cells were treated with PPARγ ligand (GW1929), RXR ligand (9-cis-
retinoic acid, 9-cRA), all at 10 µM, for 24 h. CYP27A1 enzyme activity was measured using
[3H]7-oxocholesterol as substrate. Activity is expressed as aqueous-soluble counts generated
in the presence or absence of the specific CYP27A1 inhibitor (GW273297x, 1 µM) and is
normalized for total cell protein. Data are presented relative to vehicle-treated controls and are
means + S.E.M. (n = 6). *Significantly different (P < 0.001) from control.
there was no evidence that activating ligands for any of these
transcription factors affected CYP27A1 expression. On the other
hand, a striking and consistent increase in CYP27A1 mRNA ex-
pression was induced by PPARγ -specific agonists GW1929 and
pioglitazone (GW6777). A third PPARγ ligand, rosiglitazone, had
a similar effect, although higher doses (100 µM) were required
(results not shown). Moreover, the PPARγ -specific antagonist
GW9662 [38] significantly reduced CYP27A1 mRNA relative to
control levels, and abolished the stimulatory effects of the PPARγ
ligands (Figure 2B).
We next determined if CYP27A1 activity was also increased
in THP-1 human macrophages treated with RXR and PPARγ
ligands. Previously, we demonstrated in HMDMs that CYP27A1
can use both cholesterol and 7-oxocholesterol as substrate [9].
As with HMDMs [9], the vast majority of the products of the
CYP27A1 reaction in THP-1 cells was found in the aqueous-
soluble fraction. Approx. 10 times more labelled cholesterol was
converted into aqueous products than could be recovered as 27-
hydroxycholesterol in cells or medium when THP-1 cells were
incubated with [3H]cholesterol for 24 h. Figure 3 shows the
aqueous-soluble counts after THP-1 cells were incubated with
[3H]7-oxocholesterol for 24 h. The specificity of the assay was
confirmed using a selective inhibitor of CYP27A1 (GW273297x
[9]). The RXR ligand, 9-cis-retinoic acid, but not the PPARγ
ligand, GW1929, significantly increased CYP27A1 activity.
Primary HMDMs express significantly higher levels of CYP27A1
than THP-1 human macrophages
Up to this point, our studies were performed in THP-1 cells. The
human THP-1 cell line can be differentiated to a macrophage-like
phenotype by exposure to PMA [24], and this is frequently used
as a convenient experimental model for primary human macro-
phages. However, CYP27A1 activity in control THP-1 cells was
at the limits of detection, and was at least an order of magnitude
lower than we had observed previously in HMDMs [9]. In a direct
c© 2005 Biochemical Society
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Figure 4 Comparison of CYP27A1 activity between THP-1 and primary
human macrophages
CYP27A1 enzyme activity was measured in terminally differentiated THP-1 cells (open bars)
and in HMDMs (closed bars), using either [3H]cholesterol (A) or [3H]7-oxocholesterol
([3H]-7-ketocholesterol) (B) as substrate. Activity is expressed as aqueous-soluble counts
generated in the presence or absence of the specific CYP27A1 inhibitor (GW273297x, 1 µM)
and is normalized for total cell protein. Data are presented relative to vehicle-treated controls and
are means + S.E.M. (n = 3) for all cell types. Significant differences (P < 0.001 or P <
0.05) are indicated.
comparison, we confirmed that activity against either [3H]chol-
esterol (Figure 4A) or [3H]7-oxocholesterol (Figure 4B) was much
higher in HMDMs than in THP-1 macrophages. We then used
QRT-PCR to quantify CYP27A1 mRNA levels in THP-1 cells,
HMDMs and a liver cell line (HepG2) (Figure 5A). mRNA levels
were substantially lower (up to 1000-fold) in differentiated THP-1
macrophages than in primary human macrophages. The mRNA
expression of the housekeeping gene PBGD was similar between
the cell types in that the threshold for all three cell types was 18–
19 cycles. The higher expression of CYP27A1 mRNA in primary
HMDMs was also reflected in relative protein levels between
the two cell types, measured by Western blot. A strong band of
CYP27A1 (approx. 60 kDa) was detected in HMDM mitochon-
dria (duplicate samples), but was detected only weakly in THP-1
cells, even when more protein was loaded for the latter (Fig-
ure 5B). Interestingly, CYP27A1 mRNA and protein expression
was also higher in HMDMs than in the liver cell line, HepG2
(Figures 5A and 5B).
THP-1 monocytes are induced to undergo differentiation by a
3-day exposure to PMA. PMA is a potent activator of protein-
kinase-C-mediated protein phosphorylation, which can cause
substantial alterations to protein structure and function. We con-
sidered that PMA treatment, besides inducing THP-1 differen-
tiation, might repress CYP27A1 expression selectively, as has
been reported previously in HepG2 cells [12]. Therefore the
effect of PMA on CYP27A1 expression and activity in HMDMs
was measured. PMA did induce a significant decrease in
CYP27A1 mRNA (approx. 60 %; P < 0.05; n = 3) in HMDMs
Figure 5 Comparison of CYP27A1 mRNA and protein expression between
THP-1, primary human macrophages and HepG2 cells
(A) CYP27A1 mRNA levels in PMA-differentiated THP-1, HMDM and HepG2 cells were compared
directly using QRT-PCR, normalized to PBGD mRNA and then expressed relative to THP-1 levels.
(B) Western blots of mitochondrial fractions isolated from terminally differentiated THP-1, HepG2
(both 20 µg per lane) and HMDMs (12 µg per lane in duplicate), after separation on SDS/10 %
PAGE and blotting with polyclonal anti-human CYP27A1.
and a corresponding significant, though lesser, decline in activity
(approx. 25%; P = 0.01; n = 5), although CYP27A1 levels were
still much higher than in PMA-differentiated THP-1 cells. The
mRNA expression of the housekeeping gene PBGD remained
unchanged in HMDMs after PMA treatment. Also, when dif-
ferentiation was induced by an alternative method independent
of PMA [39], the level of CYP27A1 expression in THP-1
macrophages was similar to PMA-differentiated cells (results not
shown). Therefore it seems likely that, while PMA may contribute,
other factors are also important in the relatively low expression
of CYP27A1 in THP-1 macrophages.
CYP27A1 is also regulated through PPARγ /RXR in primary human
macrophages
To determine if our findings in THP-1 cells hold in primary macro-
phages, we repeated key experiments in HMDMs. AcLDL-load-
ing of HMDMs increased mRNA expression levels of the LXR
target gene, ABCA1 [2.7 +− 0.3 (mean +− S.E.M.), when the level
in non-loaded cells was set as 1]. As observed in THP-1 cells,
AcLDL-loading of HMDMs did not alter CYP27A1 mRNA
levels (1.24 +− 0.15). Message levels and the enzyme activity of
CYP27A1 are also significantly increased when HMDMs were
treated either with the RXR ligand, 9-cis-retinoic acid, or with
the PPARγ ligand, GW1929, but not with the LXR ligand, 22(R)-
hydroxycholesterol (Figure 6).
DISCUSSION
The wide tissue distribution of CYP27A1 suggests a metabolic
role beyond hepatic bile acid synthesis. In particular, its relatively
high expression in tissue macrophages has led to the suggestion
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Figure 6 CYP27A1 expression is regulated by PPARγ and RXR ligands in
primary human macrophages
(A) HMDMs were treated with PPARγ ligand (GW1929), RXR ligand (9-cis-retinoic acid,
9-cRA) or LXR ligand [22(R)-hydroxycholesterol, 22(R)HC], all at 10 µM, for 24 h. CYP27A1
mRNA levels were measured using QRT-PCR, normalized against PBGD mRNA levels.
(B) Cells were treated for 24 h with GW1929, 9-cRA or 22(R)HC (10 µM) in medium containing
[3H]7-oxocholesterol, and activity was measured after 24 h as described in the Experimental
section. Data are presented relative to vehicle-treated controls and are means + S.E.M. (n = at
least 3). Significantly different from control: *P < 0.01, **P < 0.001.
that the enzyme is important in cholesterol metabolism and elim-
ination from these cells. Interest in a role for CYP27A1 in chol-
esterol elimination from macrophages was stimulated by observ-
ation of tendon xanthomas containing cholesterol-loaded
macrophages in CTX subjects and the increased risk of athero-
sclerosis in these individuals. In non-CTX subjects, CYP27A1 is
expressed in cholesterol-loaded macrophages in atherosclerotic
lesions [7,11] and in tendon xanthomas [40]. Many other proteins
involved in control of cholesterol metabolism [ABCA1, ABCG1
(ATP-binding cassette protein G1), apoE, SREBP (sterol-regu-
latory-element-binding protein) 1c, HMG-CoA (3-hydroxy-3-
methylglutaryl-CoA) reductase, LDL receptor, etc.] are regulated
by cellular cholesterol status, through either LXR- or SREBP-
dependent transcriptional control [41,42]. However, we found
that neither cholesterol loading nor direct addition of LXR ligands
altered CYP27A1 expression in human macrophages.
We excluded the possibility that the level of LXR expression
could be limiting the responsiveness of CYP27A1 transcription,
because another LXR-dependent gene (ABCA1) was stimulated
by either cholesterol loading or LXR ligands in the same cells.
This demonstrates that CYP27A1 expression is independent of
cell cholesterol levels in general and of LXR-dependent control
of transcription. The reason for strong expression of CYP27A1
in cholesterol-loaded macrophages in vivo therefore remains to
be determined. Other potential contributing factors are the stimu-
latory effects of monocyte/macrophage differentiation, which is
associated with increased CYP27A1 expression in vitro [14], and
increased PPARγ expression in lesion macrophages (see below).
While unaffected by cellular cholesterol levels, expression
of CYP27A1 was responsive to lipid ligands for other nuclear
receptors. Thus 9-cis-retinoic acid (an RXRα ligand) consistently
and strongly stimulated CYP27A1 expression and activity. How-
ever, of the panel of ligands for possible RXRα partners tested,
only those for PPARγ substantially increased CYP27A1 expres-
sion. Its reversal by a PPARγ antagonist demonstrated the
specificity of this effect.
Recent studies have indicated that activation of macrophage
PPARγ is generally anti-atherogenic and anti-inflammatory [43].
Despite stimulating expression of macrophage CD36, a putative
receptor for oxidized LDL, PPARγ agonists reduced athero-
sclerosis in mice [44]. This was probably, at least partly, due to
stimulation of macrophage cholesterol export, through increased
expression of ABCA1, ABCG1 and apoE. The present study raises
the possibility that up-regulation of CYP27A1 may also contribute
to the enhanced sterol efflux caused by PPARγ -agonists.
Expression of both PPARγ [45] and CYP27A1 [14] is up-
regulated during monocyte differentiation to macrophages. These
proteins are both highly expressed in human lesion macrophage
foam cells [7,11,45,46], which is consistent with a functional role
for PPARγ in the control of CYP27A1 expression. It has been
reported that the pattern of PPARγ protein expression is highly
correlated with oxidation-specific epitopes in human lesions [46].
If CYP27A1 similarly co-localizes with oxidation-specific
epitopes, it could have a role in metabolism of potentially athero-
genic oxysterols in macrophage foam cells [9].
It is possible that the PPARγ ligands could be acting directly on
the CYP27A1 promoter by binding to a PPRE (PPAR-response
element), a direct hexanucleotide repeat separated by one nucleo-
tide (also known as a DR1 element). We have performed in silico
analysis of the proximal 2 kb of CYP27A1 5′ flanking sequence
for potential PPREs and, although there are several partial matches
to a consensus sequence, there are no prime candidates. A detailed
promoter analysis would be necessary to identify if any of the
partial matches act as functional PPREs. It could also be the case
that a PPRE may lie further upstream or that a PPARγ ligand is up-
regulating CYP27A1 gene expression via an indirect mechanism.
While their relative responses to nuclear receptor ligands were
very similar, there were large differences in CYP27A1 levels be-
tween primary HMDMs and THP-1 macrophages. One contribu-
tory factor to the difference may be the suppressive effect of PMA
on CYP27A1 expression, as PMA did suppress expression when
added to HMDMs. This could be mediated through activation of
protein kinase C by PMA, leading to cytokine release, as inter-
feron-γ decreases CYP27A1 expression in human arterial endo-
thelium and macrophages [15]. However, this could not com-
pletely account for the very large difference between primary
human macrophages and the cell line, and highlights the caution
that should be exercised in applying results obtained from con-
tinuous cell lines to the in vivo condition.
While both 27-hydroxycholesterol and 3β-hydroxy-5-choles-
tenoic acid are generated by macrophages during CYP27A1-de-
pendent metabolism [8], it is important to note that the majority of
the products are much more polar and partition into the aqueous
phase during Folch extraction of cells or tissues [9]. Normal assay
protocols, designed to extract and measure the primary products,
27-hydroxycholesterol and 3β-hydroxy-5-cholestenoic acid, dis-
card this fraction and so significantly underestimate macrophage
CYP27A1 activity. We have not determined the identity of these
products, but they are likely to include bile acid-like molecules.
Their functional importance in macrophage biology is not known
and merits further study.
In summary, we have provided evidence to show that expression
of CYP27A1 is independent of cellular cholesterol status, but
is controlled through PPARγ /RXR in human macrophages, and
suggest that this may explain its high expression in human
c© 2005 Biochemical Society
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atherosclerotic foam cells. Our finding that the important macro-
phage sterol elimination pathway catalysed by CYP27A1 is up-
regulated by PPARγ may represent a key previously unrecognized
mechanism by which PPARγ protects against atherosclerosis.
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